PatientPod
March 18th, 2026
From Tech Transfer to Trials: David Craig’s Mission in Muscular Dystrophy
In this episode of PatientPod, George Kramb sits down with David Craig, CEO and co-founder of Sarcomatrix, to talk about what it really takes to build in biotech, advance therapies in muscular dystrophy, and navigate the gap between scientific innovation and real-world execution.
.webp)
About the Speakers
David Craig is the CEO and co-founder of Sarcomatrix, with decades of experience across biotech leaders like Amgen and Gilead, where he helped build commercial operations, infrastructure, and go-to-market strategy. He now leads the development of novel therapies in muscular dystrophy, combining deep scientific understanding with practical execution in drug development.
George Kramb is the co-founder and CEO of PatientPartner and host of The Patient Pod, where he focuses on bridging patient experience with clinical trial performance through peer mentorship and engagement strategies. A Forbes 30 Under 30 honoree, he brings a founder’s perspective to improving access, adherence, and outcomes in healthcare.
Together, they bring a conversation that connects biotech building, patient impact, and the realities of advancing therapies from early research to real-world application.
George Kramb is the co-founder and CEO of PatientPartner and host of The Patient Pod, where he focuses on bridging patient experience with clinical trial performance through peer mentorship and engagement strategies. A Forbes 30 Under 30 honoree, he brings a founder’s perspective to improving access, adherence, and outcomes in healthcare.
Together, they bring a conversation that connects biotech building, patient impact, and the realities of advancing therapies from early research to real-world application.
Here's exactly what you'll learn:
David shares his journey — from early days at companies like Amgen and Gilead, to leading SarcoMatrix and advancing new therapies in muscular dystrophy. Together, we unpack what it really takes to build in biotech, including:
Why progress in complex diseases often comes from incremental gains and combination therapies, not single breakthroughs
What the current reality of gene editing and CRISPR looks like beyond the hype
How early-stage biotech teams can align clinical, commercial, and operational strategy from the start
A practical path for aspiring founders, from building technical depth to developing real business execution
.avif)
Melissa B.
Sobi Pharmaceuticals
.avif)
Brad A.
Mainstay Medical
Sara W.
Marketing Director | Rare Disease
Want to be featured on the next episode of PatientPod?
Have a unique perspective on patient engagement or healthcare innovation?
We’re always looking for forward-thinking leaders to join us on PatientPod.
Share your info below, and our team will be in touch.
We’re always looking for forward-thinking leaders to join us on PatientPod.
Share your info below, and our team will be in touch.
Thank you! Your submission has been received!